Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Metformin Eicosapentaenoate (TP-101)
NCT02113163Phase 1Completed
- Sponsor
- Thetis Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of metformin eicosapentaenoate in type 2 diabetes mellitus (T2DM) and hypertriglyceridemia (2 cohorts), sponsored by Thetis Pharmaceuticals. Primary endpoint: Area Under the Curve at 12 hours. Started Mar 2014; status: completed.
02
Drugs
metformin eicosapentaenoate
03
Conditions
type 2 diabetes mellitus (T2DM)hypertriglyceridemia
Beyond the preview
Go deeper on NCT02113163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113163.